<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="18141">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01675310</url>
  </required_header>
  <id_info>
    <org_study_id>Conacyt 151819</org_study_id>
    <secondary_id>INPer (Mexico)</secondary_id>
    <nct_id>NCT01675310</nct_id>
  </id_info>
  <brief_title>Medical Nutrition Therapy Plus Transgestational Metformin For Preventing Gestational Diabetes In High Risk Mexican Women</brief_title>
  <official_title>EFFECTIVITY OF MEDICAL NUTRITION THERAPY PLUS TRANSGESTATIONAL METFORMIN FOR PREVENTING THE INCIDENCE OF GESTATIONAL DIABETES MELLITUS IN HIGH RISK MEXICAN WOMEN.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Council of Science and Technology, Mexico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes</source>
  <oversight_info>
    <authority>Mexico: Institutional Review Board National Institute of Perinatology</authority>
    <authority>Mexico: National Council of Science and Technology (CONACYT)</authority>
    <authority>Mexico: COFEPRIS Federal Comission for Prevention of Sanitary Risk</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gestational diabetes mellitus is one of the most frequent complications of pregnancy, that
      affect between 1 to 14% of population around the world.

      There is a few studies to prevent gestational diabetes mellitus in high risk women as
      Mexican population.

      Metformin has been used during pregnancy in women with gestational diabetes and women with
      polycystic ovary syndrome, with acceptable security for mother and fetus.

      Metformin decrease the insulin resistance and weight gain, we believe that metformin may be
      decrease the risk of gestational diabetes mellitus in high risk women.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Anticipated">January 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Gestational diabetes mellitus</measure>
    <time_frame>27-28 weeks of gestation</time_frame>
    <safety_issue>No</safety_issue>
    <description>oral glucose tolerance test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>insulin resistance</measure>
    <time_frame>At birth</time_frame>
    <safety_issue>No</safety_issue>
    <description>measure of insulin resistance by HOMA-IR, sample of umbilical cord</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Pregestational Obesity (BMI &gt; 27kg/m2)</condition>
  <condition>History of Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>medical nutrition therapy + metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>medical nutrition therapy plus trans-gestational metformin (850mg 2 times day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>medical nutrition therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>medical nutrition therapy without trans-gestational metformin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>medical nutrition therapy + metformin</intervention_name>
    <arm_group_label>medical nutrition therapy + metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Medical nutrition therapy</intervention_name>
    <description>medical nutrition therapy</description>
    <arm_group_label>medical nutrition therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Mexican women with pregnancy &lt; 16 weeks of gestation, normal oral glucose tolerance
             75g-2h test and 3 or more criteria:

               1. Body mass index &gt; 27 kg/m2

               2. Maternal age &gt;25

               3. History of infertility with polycystic ovary syndrome

               4. History of macrosomic newborn (Weight &gt;4000g)

               5. History of diabetes mellitus in first or second degree.

               6. History of gestational diabetes in previous pregnancy

        Exclusion Criteria:

          -  Any form of pregestational diabetes

          -  Fasting glucose &gt; 126 mg/dL at first prenatal visit.

          -  seric creatinine &gt; 1.5 mg/dL

          -  Hyperthyroidism

          -  Heart disease

          -  Hepatic disease

          -  Renal diseases

          -  Epilepsy

          -  Lupus

          -  Chronic hypertension.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Enrique Reyes-Muñoz, MD</last_name>
    <phone>52 (55) 55209900</phone>
    <phone_ext>299</phone_ext>
    <email>dr.enriquereyes@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carlos Ortega-Gonzalez, MD</last_name>
    <phone>52 (55) 55209900</phone>
    <phone_ext>307</phone_ext>
    <email>ortegagonzalez@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Institute of Perinatology</name>
      <address>
        <city>Mexico</city>
        <zip>11000</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enrique Reyes-Muñoz, MD</last_name>
      <phone>52 (55)55209900</phone>
      <phone_ext>299</phone_ext>
      <email>dr.enriquereyes@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Carlos Orega-Gonzalez, MD</last_name>
      <phone>52 (55) 55209900</phone>
      <phone_ext>307</phone_ext>
      <email>ortegagonzalez@hotmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <lastchanged_date>August 28, 2012</lastchanged_date>
  <firstreceived_date>August 27, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Nacional de Perinatologia Isidro Espinosa de los Reyes</investigator_affiliation>
    <investigator_full_name>ENRIQUE REYES-Munoz MD</investigator_full_name>
    <investigator_title>Clinical Reseach</investigator_title>
  </responsible_party>
  <keyword>obesity, polycystic ovary syndrome, gestational diabetes</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
    <mesh_term>Diabetes, Gestational</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
